脓毒症的抗凝治疗  

Anticoagulant therapy for sepsis

作　　者：陈琳 曹斓馨[1] 张根生 Chen Lin;Cao Lanxin;Zhang Gensheng(Department of Critical Care Medicine,The Second Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou 310009,China;Department of Neurosurgery,Jinhua Hospital Affiliated to Zhejiang University School of Medicine,Jinhua 321000,China)

机构地区：[1]浙江大学医学院附属第二医院重症医学科,浙江杭州310009 [2]浙江大学医学院附属金华医院神经外科,浙江金华321000

出　　处：《血栓与止血学》2023年第4期165-169,共5页Chinese Journal of Thrombosis and Hemostasis

基　　金：浙江省医药卫生科技计划项目(2021KY174)。

摘　　要：脓毒症是临床常见综合征,具有高发病率和高致死率。脓毒症患者常伴有凝血功能障碍,导致病情复杂化,增加死亡率。因此,抗凝治疗已成为脓毒症治疗的一个重要方面。脓毒症发病机制尚不明确,异质性大,抗凝时机、抗凝持续时间等抗凝策略尚缺乏高质量研究。本文拟对目前脓毒症抗凝治疗进展作一述评。Sepsis is a common clinical syndrome with high morbidity and mortality.Patients with sepsis are often accompanied by coagulopathy,leading to comorbidity and increased mortality.Therefore,anticoagulant therapy has become an important aspect of sepsis treatment.The pathogenesis of sepsis is still unclear,with large heterogeneity,and high-quality research on anticoagulant strategies such as anticoagulant timing and anticoagulant duration is still lacking.This paper intends to review the current progress of anticoagulant therapy for sepsis.

关 键 词：脓毒症 凝血功能障碍 抗凝治疗 低分子肝素 普通肝素 

分 类 号：R459.7[医药卫生—急诊医学]